Epirus Biopharmaceuticals Inc. (EPRS) 8.74 $EPRS How

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Epirus Biopharmaceuticals Inc. (EPRS) 8.74 $EPRS

How Novartis Drug Approval Makes Biosimilar Makers Ripe for Acquisition
at The Street - Tue Mar 31, 8:13AM CDT
Pfizer, Teva and Actavis are potential consolidators, while Momenta, Coherus and Epirus lead the list of likely targets.
EPRS: 8.74 (-0.25), AMGN: 169.10 (+0.64), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62), CHRS: 24.79 (-0.89)

Raising Price Target On Epirus Biopharma - The Biosimilar Revolution Has Started
Jason Napodano, CFA - at Seeking Alpha - Wed Mar 25, 1:13PM CDT
On March 23, 2015, Epirus Biopharmaceuticals, Inc. (NASDAQ: EPRS ) reported financial results for the fourth quarter and full year ending December 31, 2014. Revenues for the fourth quarter and year were negligible, and the company indicated that in...
EPRS: 8.74 (-0.25)

EPIRUS Biopharmaceuticals to Host Biosimilar Key Opinion Leader Meeting and Webcast on March 30
GlobeNewswire - Wed Mar 25, 6:00AM CDT
EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, today announced that it will host a Key Opinion Leader (KOL) breakfast in New York City focused on offering insights into the evolution of the U.S. regulatory landscape, along with a clinician's perspective on the approval and use of biosimilars. The event and live webcast will take place on Monday, March 30, 2015 from 8:00 to 9:15 a.m. Eastern Time.
EPRS: 8.74 (-0.25)

Biosimilar firms move up
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 12:20PM CDT

EPRS: 8.74 (-0.25), PFNX: 15.12 (+0.42), CHRS: 24.79 (-0.89)

EPIRUS Biopharma Q4 and FY14 results
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 6:09AM CDT

EPRS: 8.74 (-0.25)

EPIRUS Biopharmaceuticals beats by $0.19
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 3:42PM CDT

EPRS: 8.74 (-0.25)

EPIRUS Reports Fourth Quarter and Fiscal Year 2014 Financial Results
GlobeNewswire - Mon Mar 23, 3:35PM CDT
EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2014.
EPRS: 8.74 (-0.25)

Nasdaq stocks posting largest percentage decreases
AP - Thu Mar 12, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
CMTL: 30.97 (+0.12), SGMS: 12.48 (+0.25), ANY: 3.33 (-0.16), PTX: 7.44 (-0.05), MRD: 19.19 (+0.06), EPRS: 8.74 (-0.25), AEPI: 53.45 (-1.99), HTHT: 22.54 (+0.06), RESN: 3.77 (-0.06), SALM: 5.43 (+0.03), ACAD: 38.55 (-0.20), LAYN: 5.58 (+0.28), INGN: 36.39 (-0.04), VRA: 14.16 (-0.69), MRVC: 8.51 (+0.15)

LifeSci Capital Initiates Coverage of EPIRUS Biopharmaceuticals
ACCESSWIRE - Wed Mar 11, 8:00AM CDT
Pure-Play Biosimilars Company with Plans to Address the Global Market
EPRS: 8.74 (-0.25)

EPIRUS to Report Fourth Quarter and Fiscal Year 2014 Financial Results on March 24, 2015
GlobeNewswire - Wed Mar 11, 6:00AM CDT
EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, today announced that it will host a conference call and webcast at 10 a.m. Eastern Time on Tuesday, March 24, 2015 to discuss fourth quarter and fiscal year 2014 financial results, and to discuss the Company's progress. The call will be led by Amit Munshi, President and Chief Executive Officer, and Tom Shea, Chief Financial Officer.
EPRS: 8.74 (-0.25)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Feb 20, 8:16AM CST

ANET: 66.27 (+0.40), FUEL: 8.97 (+0.01), EPRS: 8.74 (-0.25), ASTI: 1.07 (+0.04), MEIP: 2.08 (-0.16), OESX: 3.16 (-0.06), GENE: 4.88 (-0.05), CLSN: 2.92 (+0.03), NVO: 56.37 (-0.17), SAAS: 10.39 (+0.05), CRC: 8.79 (-0.18), CLRX: 0.95 (unch), NDLS: 19.73 (+0.31), TRUE: 15.72 (-0.26)

Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 206.93 (-3.92), ACT: 295.22 (+0.69), MDT: 78.01 (+0.93), XON: 44.53 (+0.36), CTIC: 1.93 (+0.09), PFNX: 15.12 (+0.42), JNJ: 100.43 (+0.13), ANTM: 152.84 (-0.04), NVAX: 8.51 (+0.09), SHPG: 253.58 (+3.70), ABBV: 64.52 (+0.91), TBPH: 18.41 (+0.18), SNY: 51.59 (+0.03), ALQA: 4.88 (+0.33), REGN: 472.63 (+9.41), ONCY: 0.80 (unch), PFE: 34.93 (+0.04), SLXP: 172.96 (+0.15), EPRS: 8.74 (-0.25), AMGN: 169.10 (+0.64), NKTR: 10.90 (+0.16), ZTS: 47.03 (-0.51), GILD: 104.18 (-1.02), ACHN: 10.01 (-0.13), GERN: 4.20 (-0.04)

EPIRUS Biopharmaceuticals (EPRS) Jumps: Stock Up 18.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 7:51AM CST
EPIRUS Biopharmaceuticals (EPRS) was a big mover last session, as the company saw its shares rise nearly 19% on the day.
EPRS: 8.74 (-0.25), AFFX: 12.57 (-0.13)

Biosimilar firms up on Remicade patent rejection
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 11:56AM CST

JNJ: 100.43 (+0.13), PFE: 34.93 (+0.04), AMGN: 169.10 (+0.64), EPRS: 8.74 (-0.25), PFNX: 15.12 (+0.42), HSP: 87.80 (+0.04), NVS: 103.45 (-0.62), CHRS: 24.79 (-0.89)

Pfizer Pays A Pretty Penny For Hospira: Here's What You Need To Know
Brendan O'Boyle - at Seeking Alpha - Tue Feb 10, 8:49AM CST

ABT: 48.35 (+1.23), TARO: 143.40 (-0.31), PFE: 34.93 (+0.04), MYL: 72.40 (-1.67), EPRS: 8.74 (-0.25), TEVA: 63.01 (-1.15), HSP: 87.80 (+0.04)

3 Medical Advancements You May Be Missing Out On
Motley Fool Staff - Motley Fool - Sun Feb 08, 10:02AM CST
Source: 3D Systems. From 3D printing to next-generation cancer killers, there are some medical innovations that could have an incredible impact on patients. Our Motley Fool analysts explain how these next-generation medical advances could reshape...
BIIB: 423.57 (+1.46), ONVO: 5.14 (+0.67), DDD: 30.55 (-0.61), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), EPRS: 8.74 (-0.25), AMGN: 169.10 (+0.64), BMY: 66.60 (-0.21), NVS: 103.45 (-0.62), CELG: 115.54 (+0.72)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 160

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Linq's $90M Bet on the Infrastructure Behind AI Agents

Updated Category News Views 193

Ninety million dollars just landed on the least glamorous part of the AI-agent rush: the pipes. Linq, the San Francisco private company, announced the round on November 18, 2026, led by Andreessen Horowitz, with returning backing from TQ Ventures, Mucker Capital and Abstract, plus new money from Anthos and Left Lane Capital. Ben Horowitz is joining the board. That is a...

Continue Reading
Mudrick Urges Doncasters to Test a Strategic Sale Now

Updated Category News Views 0

Castings are rarely glamorous until nobody can get them, and Mudrick Capital is betting that ugly little industrial reality could make Doncasters worth far more in a takeover than the market currently credits. The event-driven investor, which says it owns roughly 4.3% of DPC Holdings Limited, has asked the board to quietly evaluate strategic alternatives, including a sale...

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 125

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 102

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 67

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 48

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 55

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 131

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading
Roof Leaks Demand Diagnosis Before the Repair Bill

Updated Category News Views 95

A brown ring on a ceiling is often the last witness, not the crime scene. That is the useful, unglamorous point in Jonathan Floyd's HelloNation discussion of roof leaks: water has plenty of ways to move after it slips past a roof's defenses. Homeowners understandably stare at the stain and assume the answer sits directly overhead. Sometimes it does. Plenty of times, it...

Continue Reading

Top 5 Most Recently Viewed Articles

BioMarin's Strong 2024 Performance Fuels 2025 Expectations

Updated Category News Views 392

BioMarin's Empowering Growth Journey Into 2025 BioMarin Pharmaceutical Inc. has marked a significant achievement with its record performance in 2024, setting a strong foundation for the upcoming year. The company demonstrated robust operational execution and is gearing up for a year of potential double-digit revenue growth as it advances its corporate strategy focusing on...

Continue Reading
Berkshire Hills Bancorp Declares Cash Dividend for Shareholders

Updated Category News Views 104

Berkshire Hills Bancorp Announces Quarterly Dividend Berkshire Hills Bancorp, Inc. (NYSE: BHLB) has recently declared a quarterly cash dividend of $0.18 per common share for its shareholders. This decision by the Board of Directors aims to reward shareholders who are on record by a specified date. Details of the Dividend Announcement The approved cash dividend will be...

Continue Reading
Maiden United Transforms Adele's Skyfall into Heavy Metal Epic

Updated Category News Views 167

Maiden United Transforms Iconic Adele Song into Heavy Metal What if Iron Maiden had recorded the legendary James Bond theme song? Maiden United, a notable tribute band dedicated to Iron Maiden, has taken that intriguing concept and turned it into reality. The band has just unveiled their latest EP entitled Agent 666, which features an electrifying heavy metal cover of...

Continue Reading
Cherokee Federal Boosts Growth with MSI, LLC Investment

Updated Category News Views 213

Cherokee Federal Expands Presence Through Strategic Investment Cherokee Federal, a division of Cherokee Nation Businesses (CNB), has recently announced a significant move in the federal contracting realm. They have acquired a majority stake in Management Science and Innovation, LLC, also known as MSI. This strategic investment marks another milestone under their...

Continue Reading
Metallurgical Coal Market Expected Growth Amid Steel Demand Spike

Updated Category News Views 125

Growth of the Metallurgical Coal Market The global metallurgical coal market is poised for significant growth, estimated at USD 95.27 billion from 2024 to 2028. This growth is largely driven by the increasing demand for steel, which is essential for numerous infrastructure projects around the world. As smart city developments surge, the necessity for high-quality steel...

Continue Reading